Clinical

Latest News


Latest Videos


CME Content


More News

Patients with chorea associated with Huntington’s disease have the first new treatment in nearly a decade. The FDA has approved Teva Pharmaceutical Industries Ltd’s Austedo (deutetrabenazine) for the treatment of chorea, which affects nearly 90% of patients with Huntington's.

The patient voice is becoming more important as healthcare moves to a value-based, patient-centered system of care, but just amplifying the patient voice is not enough. There needs to not only be amplification, but also a constructive response from the health system, said Thomas Lee, MD, chief medical officer at Press Ganey, during his presentation at the National Quality Forum Annual Conference.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo